Antitumor immune responses are associated with proinflammatory cytokines, whereas tumor-developing animals generally have increased the production of immunosuppressive cytokines. Here, we show that splenocytes from C57Bl/6 mice resistant to low doses of B16F10-Nex2 melanoma cells produced twofold or higher interferon-g (IFN-g)/interleukin-10 (IL-10) ratios, whereas cells from tumor-bearing animals produced predominantly IL-10. IL-10-knockout (IL-10KO) mice were significantly more resistant to B16F10-Nex2 development, producing increased amounts of IL-12 and IFN-g. To neutralize IL-10 in vivo, aiming at cancer therapy, recombinant eukaryotic plasmid expressing the soluble extracellular region of the murine IL-10 receptor a-chain was constructed (pcDNA3-sIL-10R). Plasmid-treated melanoma-challenged animals showed extended survival time, the protective response was IFN-g dependent and enhanced by co-immunization with a plasmid expressing IL-12. Dendritic cells (DCs) from IL-10KO mice, primed with B16F10-Nex2 antigens (TAg), secreted increased amounts of T-helper 1-type cytokines and increased the expression of surface activation markers. Vaccination of C57Bl/6 mice with TAg-activated IL-10KO DCs, as well as with TAg-primed DCs from C57Bl/6 mice transfected with pcDNA3-sIL10R plasmid, significantly increased animal survival. In conclusion, an IFN-g-dependent protective response was induced against B16F10-Nex2 cells by neutralization of IL-10 with pcDNA3-sIL10R plasmid. This effect was enhanced by association with IL-12 gene therapy (80% protection), and could be mediated by TAg-primed DCs.
Introduction
Most of the diverse nonspecific and specific antitumor approaches that stimulate the immune system, aiming at a protective response and destruction of tumor cells, have shown limited clinical efficacy so far. Failures in cancer treatment can be explained, at least in part, by tumorinduced immune suppression. A large number of cytokines, hormones and other molecules secreted by tumors and by local recruited immune cells were shown to have immunomodulating properties. A frequently studied immune response is the increased production of type-2 cytokines that is associated with tumor development in tumor-bearing animals and cancer patients. [1] [2] [3] [4] Early effectors of antitumor immunosurveillance must perform the critical tasks of producing interferon-g (IFN-g) and killing the target cells. 5 A significant number of reports on models of primary tumor formation give support to these requirements. Relevant cellular sources of IFN-g in the immunosurveillance include the gd-T cells that were shown to play an important role in developing a protective antitumor response. 6 IFN-g promotes the generation of tumor-specific CD4 þ T-helper 1-type (Th1) T cells and cytolytic T cells, as well as the activation of macrophages with cytocidal activity, thus fostering an antitumor response mediated by adaptive and innate immunity. 7 Furthermore, IFN-g upregulates tumor immunogenicity, which may explain tumor detection and elimination in immunocompetent hosts. 5 Accumulation of IFN-g, as in IFN-g-receptor knockout mice, also leads to resistance to syngeneic tumor implants that express IFN-g receptor owing to a direct antitumor effect of the cytokine. 8 Also in support of the protective role of IFN-g in cancer development, 17 out of 25 significantly altered genes in T and B cells from melanoma patients were IFNstimulated genes, indicating that defects in IFN signaling are dominant mechanisms of immune dysfunction in cancer patients. 9 Defects in lymphocyte IFN signaling were also observed in human breast and gastrointestinal cancers. 10 Cancer immunosurveillance can eliminate a significant number of transformed cells. In experimental models, the subcutaneous implantation of a limited number of tumor cells may result in tumor-resistant animals. Using B16F10 murine melanoma cells, we observed that the low percentage of tumor-resistant mice (2-3%) always showed a twofold or higher ratio of IFN-g/interleukin-10 (IL-10), whereas tumor-developing animals had inverse ratios, with IL-10 being the predominant cytokine. The opposing effects of these cytokines are directly related to the cells producing them and their numbers. An appropriate example is that of tumor-infiltrating T lymphocytes. The presence of IFN-g-producing CD8
þ T cells and CD4 þ helper T cells is beneficial to combat the tumor, whereas that of IL-10-and transforming growth factor-b-(TGF-b) producing CD4 þ CD25 þ and CD8 þ Treg is detrimental. 11, 12 Using a model of colon carcinoma cells (CT26), it was shown that in vitro neutralization of anti-TGF-b and IL-10 enhanced CTL responses against the tumor cells. In vivo, depletion of CD4 þ T cells increased IFN-g production by CD8
þ T cells and delayed tumor development. 12 In a study of metastatic melanoma patients, it was observed that plasma concentrations of type-2 cytokines, IL-4, IL-5, IL-10 and IL-13, in tumor-bearing patients were significantly higher than those with resected melanomas. 13 High numbers of CD4 þ CD25 high Foxp3 þ regulatory T lymphocytes secreting IL-10 and TGF-b were described in lymph nodes of metastatic patients. 14 Experimentally, during tumor progression, the number of IL-10-secreting CD4 þ T cells and NK cells increased in the spleens of mice inoculated subcutaneously with B16F10 melanoma cells, whereas the number of IFN-gsecreting CD4
þ T lymphocytes and NK cells declined dramatically. 15 IL-10 is a pleiotropic cytokine secreted by B lymphocytes, eosinophils, mast cells, macrophages, dendritic cells (DCs), NK cells and several subsets of T lymphocytes, such as CD8 þ , CD25 þ Foxp3 þ and antigen-driven regulatory CD4 þ T cells. This interleukin acts as a regulator of the protective inflammatory response in several infections, but if it is overexpressed, it plays the role of an immunosuppressive cytokine, inhibiting proinflammatory cytokine production, the expression of co-stimulatory molecules and major histocompatibility complex (MHC) class II antigens, as well as the general antigen-presenting function of macrophages and DCs (reviewed in O'Garra et al. 16 ). In this study, we show that the susceptibility of C57Bl/6 mice to B16F10 melanoma is associated with increased production of IL-10 by immune cells, and that the neutralization of this cytokine by gene therapy increased tumor rejection in vivo. This protective response was increased by the association with IL-12-expressing plasmid, and adoptive transfer of ex vivo tumor-activated and IL-10-neutralized DCs induced a significant protective response in mice challenged with B16F10-Nex2 melanoma cells.
Materials and methods

Animals
Inbred male C57Bl/6 (wild-type: WT) mice, 6-8 weeks old, were purchased from CEDEME (Centro de Desenvolvimento de Modelos Experimentais, UNIFESP, Sa˜o Paulo, Brazil). IL-10 genetically deficient (IL-10-knockout: IL-10KO) mice were housed and bred in specific pathogen-free conditions at the Cell Biology Animal Facility (UNIFESP). In all experiments, agepaired animals were used, and IL-10KO animals were treated before and during experiments with 0.04% benzoilmetronidazol on drinking water due to natural colitis development. 17 Tumor cell line and cell culture conditions B16F10-Nex2 is a subline from B16F10 murine melanoma cell line, 18 isolated at the Experimental Oncology Unit (UNONEX, Sa˜o Paulo, Brazil) and characterized by low immunogenicity and moderate aggressiveness. 19 Cells were maintained in RPMI-1640 medium (pH 7.2), supplemented with 10% heat-inactivated fetal calf serum, 10 mM Hepes (N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid) and 24 mM NaHCO 3 (all from GIBCO, Minneapolis, MN), and 40 mg ml À1 gentamycin sulfate (Hipolabor Farmaceˆutica, Minas Gerais, Brazil).
Preparation of B16F10-Nex2 cell lysate A suspension (5 Â 10 6 cells per ml) of in vitro cultured B16F10-Nex2 cells was lysed by sonication at 40 Hz (five cycles of 12 s, sample maintained on ice) and the efficiency of the method was checked by light microscopy. The sonicated cell suspension was g-irradiated (600 rads) for sterilization. Aliquots were kept at À80 1C.
pcDNA3-sIL-10R construction
To construct the eukaryotic expression vector of the soluble extracellular portion of the murine IL-10 receptor (sIL-10R), the sequence corresponding to this domain (amino acids 1-189) was cloned from lipopolysaccharideactivated macrophages. Briefly, bone marrow-derived murine macrophages were stimulated for 30 h with 200 ng ml À1 of lipopolysaccharide, and RNA extractions were carried out using Trizol reagent (Invitrogen, Sa˜o Paulo, Brazil), following the manufacturer's instructions. In order to improve reverse transcription-polymerase chain reaction (RT-PCR) amplification, a preliminary gene-specific cDNA synthesis using 'Thermo Script RT-PCR System' (Invitrogen) and a 3 0 murine IL-10R-specific primer (reverse, 5 0 -TGGAGCCTGGCTAGCTG GTCACAGTAGGTCT-3 0 ; Ho et al.
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) was carried out. This specific cDNA was then used as template for PCR amplification of sIL-10R using forward (5 0 -ATGTTGTC GCGTTTGCTCCC-3 0 ) and reverse (5 0 -CCTGTTTCAC TCTCTTGGTTG-3 0 ) primers. A PCR product of 560 bp was purified using 'Bioclean for Purification of DNA Bands' (Biotools, Sa˜o Paulo, Brazil) and cloned into a pGEM-T vector (Promega, Madison, WI). The insert was automatically sequenced using as primers the sequences corresponding to T7 (sense) and SP6 (antisense) vector promoters, and the sequence compared with those available in the NCBI GenBank (ID 16154). Nucleotide sequencing was carried out at the Human Genome Research Center, Sa˜o Paulo University (USP). The insert was then subcloned into a NotI restriction site of a pcDNA3 vector (Invitrogen), which was used to transform Escherichia coli DH5a-competent cells by heat shock. Plasmids from a selected clone were purified in CsCl gradient with ethidium bromide after ultracentrifugation at 500 000 g for 16 h (Beckman, Coulter, CA, VTi 90 rotor), followed by washing with saturated butanol to remove the ethidium bromide. Plasmids were precipitated with ethanol 100% for 16 h, washed twice with ethanol 70%, then re-suspended in sterile phosphate-buffered saline (PBS) and stocked at À20 1C.
Analysis of sIL-10R expression by transfected cells B16F10-Nex2 cells were transfected with pcDNA3-sIL10R plasmid using DOTAP reagent, following the manufacturer's instructions (Roche Applied Science, Indianapolis, IN). G418-resistant cells were selected and expanded in vitro. The sIL-10R mRNA was detected by RT-PCR using the same primers previously used for gene cloning. Primers for b-actin were used as control (forward, 5 0 -CAGAGCAAGAGAGGGATCCTGA-3 0 ; reverse, 5 0 -TGATCCACATCTGCTGGAAGGT-3 0 ). For intracellular detection of the expressed recombinant protein, transfected cells were permeabilized with PBS containing saponin 0.05%, after pretreatment for 20 min with PBS containing 0.05% saponin and 1% paraformaldehyde. Permeabilized cells were incubated during 1 h with phycoerythrin-conjugated anti-mouse murine IL-10R monoclonal antibody (mAb) (CD210, clone 1B1.3a; BD Pharmingen, San Jose, CA), fixed with 2% paraformaldehyde in PBS and fluorescence was measured in a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA). Data were collected for 10 000 viable cells and analyzed using the CellQuestPro software (Becton Dickinson, San Jose, CA).
Immunoprecipitation detection of sIL-10R in culture supernatants The secretion of the transgenic molecule was verified by immunoprecipitation. Transfected B16F10-Nex2 cell culture supernatant was incubated with murine mAb anti-IL-10R (BD Pharmingen) in RIPA (radio immunoprecipitation assay) buffer (1.5 M NaCl, 0.5 M Tris, 10% NP40 at pH 7.5) for 16 h at 4 1C. Protein A-Sepharose beads (Sigma Aldrich, Saint Louis, MO) were added and the suspension was further incubated for 4 h at 4 1C. After centrifugation, beads were washed three times in RIPA buffer. Proteins were eluted by the addition of sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer and by heating the sample at 95 1C for 3 min. Samples were analyzed by standard 12.5% polyacrylamide gel electrophoresis (SDS-PAGE). Separated proteins were then transferred to nitrocellulose membranes (100 V, 1 h), and membranes were stained with Ponceau-S solution (0.1% Ponceau in 10% acetic acid) to check the efficiency of the method. Every step was followed by several washings with PBS-0.05% Tween. 20 Membranes were blocked with PBS containing 5% skim milk (PBS-milk 5%) for 2 h at room temperature. Anti-IL-10R (BD Pharmingen) was diluted 1:500 in PBS-1% skim milk and incubated for 16 h at 4 1C, following incubation with anti-rat streptavidin-peroxidase-conjugated immunoglobulin G (Sigma Aldrich) diluted 1:1000 in PBS-1% skim milk for 1 h at 37 1C. Detection was performed with Immobilon Western Substrate (Millipore, Sa˜o Paulo, Brazil) diluted 1:5 in PBS and membranes were exposed to X-ray film (Kodak, Sa˜o Paulo, Brazil) for 15 min.
Macrophage and DC maturation from murine bone marrow progenitors Primary cultures of DCs were obtained from C57Bl/6 or IL-10KO bone marrow progenitors as described previously. 21 Briefly, bone marrow cells were collected and cultured ex vivo in RPMI-1640 medium (pH 7.2), supplemented with 10% fetal calf serum, 50 mM 2-mercaptoethanol, 100 nM amino acids supplement (GIBCO), 30 ng ml À1 of granulocyte-macrophage colony-stimulating factor and 10 ng ml À1 of IL-4 (both from Peprotech, Colonia Banjidal, DF, Mexico). Culture medium was replaced with fresh medium on day 4, and non-adherent cells were harvested and used as bone marrow-derived DCs on day 7. Macrophages were obtained from bone marrow precursors by culturing the cells in RPMI-1640 medium supplemented with 20% fetal calf serum and 30% L929 cell-conditioned medium as described previously. 22 Culture medium was replaced with fresh medium on day 4, and adherent cells were harvested and used as bone marrow-derived macrophages on day 7.
Fluorescence-activated cell sorting
For the detection of surface activation markers, bone marrow-derived DCs from C57Bl/6 or IL-10KO mice were cultured at 5 Â 10 5 cells per well, in 12-well plates, for 24 h in the presence of 100 U ml À1 of murine IFN-g (Peprotech) and the B16F10-Nex2 cell lysate (equivalent to 10 4 cells per well). Cells were harvested and stained with phycoerythrin-or fluorescein isothiocyanate-conjugated anti-MHC class II, anti-CD40, anti-CD80 or anti-CD86 antibodies (BD Pharmingen) for 1 h on ice, and then fixed with 2% paraformaldehyde in PBS. Fluorescence was measured in a FACSCalibur flow cytometer (BD Biosciences). Data were collected for 10 000 viable cells and analyzed using the CellQuestPro software (Becton Dickinson). For intracellular IFN-g and IL-10 quantification, 10 4 B16F10-Nex2 cells were subcutaneously inoculated in mice and after 25 days splenocytes were harvested. Erythrocytes were lysed (0.1 M NH 4 Cl, pH 7.2) and 4 Â 10 6 cells per ml were stimulated ex vivo for 8 h with phorbol myristate acetate (PMA) (10 ng ml À1 ) and ionomycin (3 mM). After washing with PBS containing 1% bovine serum albumin, 10 6 cells per sample were treated with PBS, 0.05% saponin, 1% formaldehyde for 20 min and for 10 min with PBS/0.05% saponin (permeabilization buffer). Intracellular staining of cytokines was performed for 1 h with biotinylated anti-IFN-g or anti-IL-10 (Pharmingen) 1:100, diluted in permeabilization buffer. After PBS washing, cells were incubated with phycoerythrin-conjugated streptavidin (BD Pharmingen) 1:200, diluted in permeabilization buffer and fixed in PBS/2% formaldehyde. Fluorescence was measured as described above.
Cytokine quantification in culture supernatants and sera by enzyme-linked immunosorbent assay Splenocytes obtained as described above (10 6 cells per well) were cultured for 3 days in 96-well plates in the presence of 10 ng ml À1 PMA and 3 mM ionomycin, or B16F10-Nex2 cell lysate (equivalent to 10 5 tumor cells per well). Cytokines (IFN-g, IL-2, IL-4, IL-6, IL-10 and IL-12) were quantified in culture supernatant. Bone marrow-derived macrophages or DCs from C57Bl/6 or IL-10KO mice (5 Â 10 5 cells per well) were cultured in 12-well plates for 3 days in the presence of 100 U ml À1 murine IFN-g and B16F10-Nex2 cell lysate (equivalent to 10 4 tumor cells per well). Cytokines (IFN-g, IL-12 and tumor necrosis factor-a: TNF-a) were quantified in culture supernatants. Sera from C57Bl/6 or IL-10KO mice subcutaneously challenged with 5 Â 10 4 B16F10-Nex2 cells were collected 11 days after tumor cell injection, and IFN-g was quantified in pooled samples of five animals, 1:10 diluted. Cytokine quantifications were performed using sandwich enzyme-linked immunosorbent assay (ELISA) kits (Peprotech) following the manufacturer's instructions.
Tumor challenge and in vivo protocols
Different numbers of B16F10-Nex2 cells were inoculated subcutaneously in the right flank and tumor evolution was monitored every 2 days using a caliper. The maximum tumor volume allowed (calculated using the formula V ¼ 0.52 Â D1 2 Â D2, where D1 and D2 are the short and long diameters, respectively) was 3 cm 3 . All animal experiments were approved by the Animal Ethics Committee at UNIFESP (protocol number 1133/8). For gene therapy, two different plasmids were used, the pcDNA3-sIL-10R and a plasmid expressing both p35 and p40 subunits of murine IL-12 under the CMV promoter (pIL-12), provided by Alexander Rakhmilevich from the University of Wisconsin. 23 A vector containing luciferase cDNA under the CMV promoter (pCMV, HebelerBarbosa et al.
24
) and an empty pcDNA3 plasmid were used as negative controls. Viable tumor cells were inoculated subcutaneously on day 0, and 100 mg of pcDNA3-sIL-10R or the empty plasmid pcDNA3 (control) were injected intradermally on days 1, 8 and 15, at the tail base. A single injection of 100 mg of pIL-12 or the control pCMV was injected on day 1. In vivo IFN-g depletion was performed using a purified anti-murine IFN-g (XMG1.2 clone) provided by Dr Joa˜o S Silva, School of Medicine, USP at Ribeira˜o Preto, Brazil. Mice were injected intraperitoneally with 250 mg of the mAb on day À1, and with 125 mg on days 1, 3, 5, 7, 9 and 11. In a vaccination protocol, animals were adoptively transferred with IL-10KO or C57Bl/6 bone marrow-derived DCs. These cells were admixed or not with B16F10-Nex2 cell lysate (equivalent to 5 Â 10 3 B16F10-Nex2 cells), and injected subcutaneously (4 Â 10 4 cells) 2 weeks and 1 week before the tumor challenge. Alternatively, sIL-10R-transfected DCs were used. For transfection, 10 7 C57Bl/6 bone marrow-derived DCs were incubated with pcDNA3 or pcDNA3-sIL-10R and DOTAP reagent (Roche Applied Science) for 12 h. After antibiotic selection for 3 days (G418, 300 ng ml À1 ; Gibco BRL Life Technologies, Hayward, CA), transfected DCs were associated with tumor cell lysate (as described above) and inoculated subcutaneously on days À4 and þ 3 of tumor challenge. The tumor challenge was carried out subcutaneously with 10 4 or 5 Â 10 4 viable B16F10-Nex2 cells, in the same flank used for DCs inoculation.
Statistical analysis
Data are represented as means±standard errors. Student's t-test was used to analyze all in vitro experiments, and Kaplan-Meier log-rank test was used to analyze in vivo experiments. In both tests, the differences were considered statistically significant when Po0.05.
Results
Susceptibility to B16F10-Nex2 murine melanoma cells is associated with increased IL-10 produced by splenocytes When C57Bl/6 mice are injected subcutaneously with syngeneic melanoma B16F10-Nex2 cells, we consistently observed a low percentage of mice that do not develop tumors, and this effect was inversely correlated with the number of inoculated cells (data not shown). In order to verify the cytokine profile in these tumor inoculated mice, we injected subcutaneously a low dose of B16F10-Nex2 cells in male C57Bl/6 mice, and the resistant animals were selected to receive a higher subcutaneous dose 60 days later, in the contrary flank. Tumor-bearing (1.5 cm 3 tumors) and tumor-resistant animals after the second challenge were analyzed for representative anti-and proinflammatory cytokine production by ex vivo tumorstimulated splenocytes, 30 days after the second tumor cell injection. Cells from tumor-free mice displayed a strong tumor-specific IFN-g production and smaller amounts of IL-6 and IL-10, suggesting the induction of a predominant protective T-helper 1-type (Th1) response. In contrast, tumor-bearing mice showed a tumor-specific IL-10 predominant response with lower IFN-g production ( Figure 1a) . The same pattern was observed when splenocytes from these animals were nonspecifically stimulated ex vivo and the intracellular contents of IFNg and IL-10 were measured. The ratio of IFN-g-to IL-10-producing cells was always higher in tumor-free than in tumor-bearing mice (Figure 1b) .
We concluded that B16F10-Nex2 melanoma development is correlated with the increased production of IL-10, and that inhibition of tumor development is associated with the induction of a protective tumor-specific Th1-type response, represented by twofold or higher IFN-g/IL-10 ratio.
Increased survival of IL-10KO mice after B16F10-Nex2 cell implantation depends on IL-12 and IFN-g We then analyzed tumor development in the absence of IL-10, using genetically deficient mice. After subcutaneous inoculation of tumor cells in IL-10 genetically deficient (IL-10KO) and WT C57Bl/6 mice, we observed that IL-10KO mice survived significantly longer than C57Bl/6 animals ( Figure 2 ). B16F10-Nex2 melanoma cells did not secrete IL-10 in vitro, and neither the cell growth required this cytokine (data not shown).
As inhibition of tumor development in C57Bl/6 mice was correlated with increased amounts of IFN-g, we investigated IL-12 and IFN-g production in IL-10KO-resistant and WT-susceptible animals.
Tumor-free IL-10KO mice showed a 10-fold increased level of IFN-g in serum compared with tumor-bearing C57Bl/6 animals ( Figure 3a) . Splenocytes from tumor-free IL-10KO mice produced higher levels of IL-12 than cells from tumor-bearing C57Bl/6 mice after ex vivo stimulation with tumor cell lysate, as measured by ELISA of culture supernatants (Figure 3b ). Although the majority of IL-10KO mice inoculated with low numbers of tumor cells was protected, some animals developed subcutaneous tumor. Splenocytes from tumor-free IL-10KO mice produced increased amounts of IL-12 and IFN-g as compared with tumor-bearing animals when tumor antigens were used for stimulation ex vivo. When a nonspecific stimulus was used (PMA and ionomycin), cells from both animals produced the same amount of IFN-g. The IL-12 production, however, was compromised in tumor-bearing animals (Figure 3c) .
IFN-g has a pivotal role in the inhibition of tumor development in the absence of IL-10, as shown after neutralization of this cytokine in vivo by anti-IFN-g mAb. IFN-g-depleted IL-10KO animals showed reduced survival, similar to that in WT C57Bl/6 animals ( Figure 3d) .
Results suggest, therefore, that the absence of IL-10 increased the IFN-g-dependent protective antimelanoma response. They also suggest that IL-10 neutralization may be beneficial to the tumor-bearing host.
Construction of a vector expressing the soluble extracellular domain of IL-10R
In vivo neutralization of IL-10 was obtained in several systems with monoclonal antibodies directed to the receptor of this cytokine. [25] [26] [27] We tested a new approach for cytokine neutralization, vaccinating mice with a plasmid expressing the extracellular portion of the murine IL-10R as a soluble decoy protein in vivo.
Using RNA from lipopolysaccharide-stimulated macrophages, we cloned the cDNA fragment corresponding to the hydrophilic N-terminal portion of murine IL-10R a-chain, mature protein and its signal peptide, comprising the extracellular region of the receptor, named here sIL-10R (Figure 4a ). This encoding sequence was inserted in an eukaryotic expression plasmid (pcDNA3) and the construction pcDNA3-sIL-10R was tested in vitro and in vivo.
No base pair exchange, deletion or inclusion was detected by nucleotide sequencing of the construction (data not shown).
B16F10-Nex2 cells were transfected with the plasmid and sIL-10R mRNA was detected by RT-PCR using the same primers used for gene cloning (Figure 4b ). Intracellular staining with an mAb directed to the murine IL-10R (CD210) showed sIL-10R protein expression by these cells (Figure 4c ). More importantly, the recombinant protein was secreted by the transfected cells as a group of three species between 30 and 45 kDa, detected by immunoprecipitation and immunoblotting with the anti-CD210 mAb (Figure 4d ). On the basis of the amino-acid sequence of the expressed protein fragment, the predicted molecular weight was 22 kDa. As shown, however, for human IL-10R, the occurrence of more than one species may be explained by different N-glycosylated fragments in the sample. Tan et al. 28 examined the extracellular portion of human IL-10R resolved as three species, and identified five possible N-glycosylation sites in the peptide sequence. The human recombinant protein was restored to the predicted molecular weight upon enzymatic deglycosylation, proving that the altered migration in electrophoresis In vivo IL-10 neutralization by gene therapy induced an IFN-g-dependent protective antimelanoma response, and this response was enhanced by IL-12-expressing plasmid C57Bl/6 mice subcutaneously challenged with B16F10-Nex2 cells and treated with subcutaneous pcDNA3-sIL-10R injections showed significantly increased survival, similar to PBS-treated IL-10KO animals. Control groups, treated with PBS or pcDNA3 empty plasmid, showed reduced survival (Figure 5a) .
Neutralization of IFN-g in pcDNA3-sIL-10R-treated animals abolished the protective effect, indicating that the protection induced by IL-10 neutralization in vivo by gene therapy depended on IFN-g (Figure 5b ).
On trying to improve the tumor-protective Th1-type response obtained with sIL-10R gene therapy, C57Bl/6 mice were treated concomitantly with a single dose of a plasmid expressing functional murine IL-12 (pCMV-IL12), as described previously. 24 Animals treated with empty plasmids were not protected, showing subcutaneous nodules before the 30th day after tumor cell inoculation, and animals treated with pcDNA3-sIL10R or pCMV-IL12 were partially protected. Treatment using a combination of both plasmids rendered a higher number of tumor-free animals 50 days after tumor cell inoculation (Figure 5c ).
These results showed that the plasmid containing a minigene encoding the extracellular domain of the murine IL-10R expressed the peptide in vivo, and that neutralization of IL-10 increased survival of B16F10-Nex2 tumorbearing mice. The association of IL-12 immunotherapy with IL-10 neutralization induced a stronger protective antitumor immune response.
Characterization of mechanisms involved in the protective immune response induced in the absence of IL-10
To further characterize the immunological mechanisms that could be involved in the protective antimelanoma response observed in the absence of IL-10, we investigated the cytokine production and the activation level of bone marrow-derived macrophages and DCs from C57Bl/6 and IL-10KO animals, stimulated in vitro with IFN-g and B16F10-Nex2 cell lysate.
In these conditions, IL-10KO macrophages produced more IFN-g, IL-12 and TNF-a, and IL-10KO DCs produced more IFN-g and IL-12, than WT C57Bl/6 cells (Figure 6a ). DCs' production of TNF-a was similar in both mouse lineages. Unstimulated DCs from C57Bl/6 and IL-10KO mice showed the same level of markers expression (Figure 6b ). In contrast, IL-10KO-activated DCs significantly upregulated the expression of CD80 and CD40, whereas the expression of MHC II and CD86 was only slightly upregulated at the cell surface (Figure 6c) .
The murine melanoma B16F10 is considered a tumor with low immunogenicity. These results, however, showed that in the absence of IL-10, DCs and macrophages were strongly stimulated by IFN-g and melanoma antigens, suggesting that these cells were more effective in antigen presentation, thus inducing a stronger antimelanomaprotective response.
As DCs from IL-10KO mice showed an activated phenotype after stimulation with melanoma antigens, we tested the ability of these cells to induce a tumorprotective response in vivo. Bone marrow-derived DCs, obtained from C57Bl/6 or IL-10KO mice, were associated with B16F10-Nex2 cell lysate and adoptively transferred subcutaneously to C57Bl/6 animals previously to tumor challenge. Animals vaccinated with DCs from C57Bl/6 mice were not protected against tumor development, even in association with tumor-specific antigens. In contrast, animals vaccinated with tumor antigen-primed DCs from IL-10KO mice were strongly protected against melanoma development (Figures 7a and b) . Interestingly, the protection has proved to be antigen-dependent, as adoptive transfer of IL-10KO DCs in the absence of tumor cell lysate did not show any statistical difference from the groups vaccinated with WT DCs (Figure 7a) .
Finally, pcDNA3-sIL10R-transfected DCs from C57Bl/6 mice were associated with tumor antigens, and used for C57Bl/6 mice vaccination. Treatment with IL-10-neutralized WT DCs increased significantly the survival of tumor cell-challenged animals (Figure 7c ).
Our results suggest that when IL-10 is neutralized by a soluble decoy receptor in vivo, DCs induce a protective antimelanoma response mainly because these cells are more effective as antigen-presenting cells in this condition.
Discussion
The natural history of melanoma suggests that this tumor can be recognized by the immune system. It has been frequently observed that, at the time of clinical detection, the primary cutaneous melanoma may exhibit histological regression, 29 and that in up to 5% patients with metastatic disease, no obvious primary lesion is identified, suggesting that the primary lesion had been completely eradicated by the immune system. 30, 31 The role of cytokines in tumor surveillance and vaccineinduced protective antitumor response has been suggested. Murine knockout models showed that animals deficient in the expression of IFN-g, type I or type II IFN receptors, or some of their downstream signal-transduction intermediates have a higher frequency of tumors compared with WT mice. 8, [32] [33] [34] Protective responses generated by several specific tumor vaccines depended on a Th1-type immunity that promotes CTL responses. 35 It has been noted, however, that single administration of proinflammatory cytokines is not sufficient to cause tumor regression, most likely owing to the recently well-characterized immunosuppressive tumor microenvironment, 36 and the observation that after specific vaccination, progressive disease is associated with antitumor Th2-type T-cell responses. 37 To date, only IFN-a and IL-2 have been accepted by the US Food and Drug Administration (FDA) for melanoma treatment. The tumor shows a poor response to cytotoxic chemotherapy, but is sensitive to immunotherapy, 38 which is a promising perspective. The immunosuppressive status established during tumor development is common to different tumor types and its reversion has been attempted by inducing a proinflammatory response, as by therapeutic vaccination and/or administration of cytokines. 35 In fact, it has been recently shown that neutralization of immunosuppressive cytokines was beneficial for the treatment of cancer. Important immunosuppressive cytokines under investigation are IL-13, TGF-b and IL-10.
Hebeler-Barbosa et al. 24 showed that IL-13 neutralization in a biochemotherapeutic protocol reduced significantly the development of B16F10-Nex2 melanoma, with 30% tumor-free animals. This protocol was based on the vaccination of mice with a plasmid expressing IL-12, associated with a cyclopalladated drug and a second eukaryotic plasmid expressing a chimera formed by the high-affinity a2-chain of IL-13 receptor coupled with the Fc portion of murine immunoglobulin G2a mAb (IL-13Ra2/Fc), as a soluble decoy receptor of the IL.
Other group used the same soluble decoy receptor for tumor treatment with similar results. [39] [40] [41] Neutralization of TGF-b by monoclonal antibodies, antisense DNA and recombinant eukaryotic vector expressing the extracellular portion of the TGF-b type II receptor/Fc chimera reduced tumor development and increased survival in several experimental tumor models. [42] [43] [44] [45] In vivo blocking of IL-10R by monoclonal antibodies stimulated protective responses able to eliminate infectious microorganisms, such as Leishmania and hepatitis C virus, [25] [26] [27] and also increased protection induced by CpG vaccination in melanoma and colon carcinoma experimental models. 46 In our experiments with murine melanoma B16F10-Nex2 cells syngeneic in C57Bl/6 mice, inhibition of tumor development was observed in animals after subcutaneous tumor cell challenge, producing twofold or higher IFN-g/ IL-10 ratios in splenocytes and serum. Splenocytes from tumor-developing animals formed, in contrast, an inverse cytokine ratio with predominant IL-10 and low IFN-g. IL-6, an inflammatory cytokine, implicated in Th2-polarized immune responses 47, 48 also had increased levels in tumor-bearing mice. Although it has been shown that tumor-bearing individuals have increased levels of IL-4 in the serum, 49 in our model, ex vivo tumor-stimulated splenocytes produced similar levels of this cytokine in tumor-bearing or tumor-resistant animals.
The association of high IL-10 and tumor development was further analyzed using IL-10KO mice, which showed increased survival and an IFN-g-dependent protective response.
As IL-10 seemed to be a key immunosuppressive cytokine in the melanoma model, we hypothesized that IL-10 neutralization in vivo would also have an inhibitory effect in tumor evolution. To address this possibility, a recombinant eukaryotic plasmid expressing the soluble extracellular region of the murine IL-10R a-chain, or IL-10R1 chain, was constructed.
ILs can be neutralized in vivo by using mAbs, RNA interference or plasmids expressing soluble receptors. Owing to the safe administration, stable expression and low price of DNA vaccines, their use is preferred to that of repeated administrations of neutralizing antibodies or soluble recombinant proteins. Moreover, as this kind of treatment does not require determination of MHC alleles of patients, and is independent of tumor antigen administration, such strategy seems to be adequate for human cancer therapy.
It has been recently shown that the recombinant soluble extracellular portion of human IL-10R was able to inhibit the binding of IL-10 to the full-length receptor, and also to antagonize biological effects of IL-10.
28,50,51
The IL-10R1 chain binds to IL-10 with high affinity and recombinant IL-10R1 exhibited antagonistic activity in vitro. 52 The extracellular region of murine IL-10R1 chain was cloned in a pcDNA3 eukaryotic vector (pcDNA3-sIL-10R), and the transfected cells expressed the protein, detected intracellularly and in the culture supernatant. Gene therapy of mice with this plasmid extended the survival of C57Bl/6 mice inoculated subcutaneously with B16F10-Nex2 cells. The protective response induced by pcDNA3-sIL10R treatment was IFN-g dependent, suggesting that the secreted protein acted as a decoy receptor, inhibiting the activity of the IL-10 cytokine in vivo.
Interestingly, when animals were concomitantly treated with a plasmid expressing murine IL-12, a stronger protection was induced, with 80% of mice being tumor free after 50 days, thus suggesting that the association of proinflammatory cytokines and neutralization of IL-10 can improve tumor therapy, as previously shown with IL-13 and TGF-b neutralization.
These results agree with previous reports that showed a correlation between melanoma development and type-2 cytokines. Kobayashi et al. 53 showed that IL-4 accelerated the formation of pulmonary metastasis in the low metastatic melanoma model with B16F1 cells. In the subcutaneous B16F10 model, Wei et al. 15 was observed early in tumor development, suggesting that increased levels of IL-10 are associated with tumor growth.
The therapeutic potential of IL-10 neutralization was further supported by Terai et al., 54 who constructed a plasmid vector expressing the extracellular domain of the human IL-10R1/immunogobulin G1 Fc fusion protein, called immunoadhesin. Human melanoma cells transfected with this vector expressed the immunoadhesin in vitro, which efficiently captured and neutralized the biological activity of the exogenously added IL-10 or endogenously produced cytokine by human tumor cells.
Tumor-specific adaptive immune responses are induced by the activation of DCs, the professional antigenpresenting cells, which capture tumor antigens and present them to naı¨ve T lymphocytes. DC-based immunotherapy in cancer aims at promoting specific immunity in the tumor-bearing host, and in this endeavor, DCs are not only antigen-presenting cells, but also act as a 'natural adjuvant' to boost vaccination. [55] [56] [57] In the presence, however, of immunosuppressive cytokines, tumor antigen cross-presentation by DCs may induce T-cell anergy or deletion. Regulatory T cells may also be stimulated instead of an antitumor protective immune response. It appears then that a single immunotherapeutic approach is not effective against established tumors.
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It has been shown that DCs isolated from IL-10KO mice have an enhanced ability to process and present bacterial antigens inducing a rapid and robust Th1-type T-cell response. 59, 60 DCs from IL-10KO mice when stimulated by hepatocellular carcinoma antigens ex vivo expressed enhanced levels of MHC II molecules (but not other activation markers, CD80, CD86 or CD40) and secreted increased amounts of IFN-g, IL-12 and TNF-a, when compared with DCs from C57Bl/6 WT mice. These tumor antigen-primed IL-10KO DCs induced a strong protective immunity against the orthotopic and subcutaneous hepatocellular carcinoma in the mouse model. 61 In this work, antigen-presenting cells (macrophages and DCs) isolated from IL-10KO mice and primed ex vivo with melanoma antigens secreted increased amounts of Th1-type cytokines, IL-12, IFN-g and TNF-a. Differing from the results by Chen et al, 61 DCs from IL-10KO mice stimulated with melanoma antigens showed increased expression of activation markers, CD40 and CD80, on the cell surface, and less of CD86 and MHC II molecules. Such activated IL-10KO DCs were used for vaccination of C57Bl/6 mice, and were as effective as in vivo gene therapy with the plasmid pcDNA3-sIL10R in the immunoprotection against B16F10-Nex2 subcutaneous challenge.
Finally, DCs from C57Bl/6 WT mice had the endogenously produced IL-10 neutralized by transfection with pcDNA3-sIL10R plasmid. The transfected cells were ex vivo primed with melanoma antigens and used for C57Bl/6 mice vaccination. Vaccinated animals, even in the absence of an exogenous factor to induce a Th1-type immune response, showed a significantly increased survival.
Demonstration of the tumor-promoting effect of an immunosuppressive cytokine does not necessarily point to the most adequate protocol to reverse this effect in WTsusceptible animals or humans. In this work, we clearly identified IL-10 as a key cytokine associated with tumor development and successfully protected tumor-challenged animals by using an IL-10 ligand and by stimulating a Th1-type response, both actions carried out by gene therapy.
We hypothesize that in mice treated with pcDNA3-sIL-10R plasmid, DCs capture melanoma antigens in the tumor microenvironment and, as IL-10 is blocked by plasmid transfection and expression of the decoy receptor, these cells are more effectively activated in their way to lymph nodes, and induce a strong Th1-type immune response. The presence of IL-12 further enhances the Th1-protective antimelanoma response.
